HWH 486
Alternative Names: HWH-486Latest Information Update: 28 Jul 2023
At a glance
- Originator Humanwell Healthcare
- Developer Humanwell Healthcare; West China Hospital Sichuan University
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in China (PO, Capsule)
- 25 Jun 2019 Preclinical trials in Rheumatoid arthritis in China (PO) before June 2019 (ChiCTR1900021131)
- 25 Jun 2019 Hubei Biological Medicine Industrial Technology Institute plans a phase I trial for Rheumatoid arthritis in China (ChiCTR1900021131)